Excellent
Fully Aligned
Patient Risk:
Low
Summary
The AI response’s mechanism-of-action and angina-related physiologic effects are directly supported by the provided FDA label excerpts in 12 Clinical Pharmacology, with no contradictions identified.
Category Scores
Accurate Statements
Amlodipine is a dihydropyridine calcium antagonist (calcium ion antagonist/slow-channel blocker) that inhibits transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, with greater effect on vascular smooth muscle than cardiac muscle.
12 CLINICAL PHARMACOLOGY (Pharmacodynamics/Mechanism of Action): dihydropyridine calcium antagonist; inhibits transmembrane calcium influx; greater effect on vascular smooth muscle cells.
Amlodipine acts as a peripheral arterial vasodilator, reducing peripheral vascular resistance and blood pressure.
12 CLINICAL PHARMACOLOGY (Pharmacodynamics/Mechanism of Action): peripheral arterial vasodilator; reduction in peripheral vascular resistance and blood pressure.
In exertional angina, amlodipine reduces afterload/peripheral resistance and reduces the rate pressure product and myocardial oxygen demand at a given level of exercise.
12 CLINICAL PHARMACOLOGY (Exertional Angina): reduces total peripheral resistance (afterload) and rate pressure product/myocardial oxygen demand.
In vasospastic (Prinzmetal's/variant) angina, amlodipine blocks coronary constriction/spasm and restores coronary blood flow.
12 CLINICAL PHARMACOLOGY (Vasospastic Angina): blocks constriction, restores blood flow; inhibition of coronary spasm responsible for effectiveness.
Negative inotropic effects can be detected in vitro, but have not been seen in intact animals at therapeutic doses; in hemodynamic studies, amlodipine has not been associated with a negative inotropic effect in intact animals and man in the therapeutic dose range, even with beta-blockers to man.
12 CLINICAL PHARMACOLOGY (Pharmacodynamics/Mechanism of Action): negative inotropic effects not seen in intact animals at therapeutic doses; hemodynamic studies not associated with negative inotropic effect in therapeutic dose range even with beta-blockers.
Unsupported Statements
Contradictions
Important Omissions
No discussion was provided regarding other labeled safety/administration elements (e.g., boxed warnings, contraindications, adverse reactions, dosing, or monitoring), but these were not part of the specific mechanism-of-action claim being evaluated.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The evaluated claims are limited to labeled mechanism-of-action and related hemodynamic/anti-anginal physiologic effects and do not introduce dosing, contraindication, or warning guidance not supported by the provided label excerpts.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Fully Aligned
Primary Issue
Suggested Improvement